A recent investigation published in Cell Reports Medicine provides important mechanistic and clinical insights into the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on body composition, addressing persistent concerns regarding potential adverse effects on skeletal muscle. GLP-1–based therapies, including semaglutide and the dual GIP/GLP-1 receptor agonist tirzepatide, have demonstrated substantial efficacy in obesity management, achieving mean weight reductions of approximately 12–19% across clinical populations, including individuals without type 2 diabetes. However, reductions in lean body mass observed during therapy have raised concerns regarding potential sarcopenic effects, particularly in vulnerable populations such as older adults.
To delineate the impact of GLP-1RAs on muscle mass and function, investigators used an integrated translational approach combining four preclinical models of diet-induced obesity with a 12-week human pilot study. In murine models, administration of tirzepatide resulted in an approximately 35% reduction in total body weight, with about 73% attributable to fat mass loss and only around 13% to reductions in lean mass. When normalized to body weight, skeletal muscle proportion was preserved and relatively improved. Functional assessments supported these findings, as treated mice showed preserved exercise capacity and endurance, performing comparably to lean controls in treadmill-based assays. In immobilization paradigms simulating physical inactivity, muscle atrophy in GLP-1–treated animals was similar to that observed with caloric restriction, indicating no additional drug-related catabolic effect.
At the molecular level, proteomic profiling of skeletal muscle tissue revealed upregulation of mitochondrial proteins and pathways associated with oxidative metabolism. These findings suggest improved muscle bioenergetics rather than degeneration and are consistent with broader metabolic effects such as improved insulin sensitivity and reduced ectopic lipid accumulation.
The human pilot cohort yielded similar results. Participants receiving semaglutide experienced clinically meaningful weight loss, with approximately 70% derived from adipose tissue reduction. Imaging demonstrated a modest decrease in the cross-sectional area of the vastus lateralis, but objective measures of muscle performance, including handgrip strength and maximal voluntary contraction, remained stable. Preservation of both absolute and relative strength indicates maintained contractile function despite reductions in total lean mass. This distinction is important because lean body mass includes non-contractile components such as extracellular water, organ mass, and connective tissue, which may account for a significant proportion of the observed decrease.
The findings indicate that GLP-1–based therapies preferentially reduce adiposity while preserving skeletal muscle function, alleviating concerns about clinically meaningful muscle wasting or frailty. Improvements in body composition, insulin sensitivity, and mitochondrial function may also contribute to reduced cardiometabolic risk and better physical performance. The long-term effects of GLP-1RAs on muscle health in diverse populations, particularly older individuals at risk for sarcopenia, remain to be determined. Larger and longer-term studies incorporating detailed functional and imaging outcomes will be necessary to confirm these findings.
In summary, current evidence suggests that GLP-1 receptor agonists such as semaglutide and tirzepatide induce weight loss primarily through fat mass reduction while preserving muscle integrity and function, supporting their continued use in the management of obesity.
Reference
- Langer HT, Gilmore NK, Hayden CMT, Roux J, Bariohay B, Rouquet T, et al. Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans. CR Med. 2026 Mar 17;7(3). doi:10.1016/j.xcrm.2026.102665 PubMed PMID: 41850248.